- Home
- MHH vs MIRM Comparison
MHH vs MIRM Comparison
Compare MHH & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MHH | MIRM |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.6M | 5.7B |
| IPO Year | 2008 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MHH | MIRM |
|---|---|---|
| Price | $6.75 | $102.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $119.85 |
| AVG Volume (30 Days) | 16.1K | ★ 847.5K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $191,371,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | $9.07 | $22.04 |
| P/E Ratio | $140.76 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.51 | $42.89 |
| 52 Week High | $8.37 | $114.99 |
Technical Indicators
Market Signals| Indicator | MHH | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 50.28 | 51.75 |
| Support Level | $6.64 | $87.26 |
| Resistance Level | $7.26 | $107.51 |
| Average True Range (ATR) | 0.40 | 6.60 |
| MACD | -0.01 | 0.47 |
| Stochastic Oscillator | 53.37 | 51.68 |
Price Performance
Historical ComparisonAbout MHH Mastech Digital Inc
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.